Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference New Mechanism Antibiotic...

Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...

Increased BARDA Award and Option Exercise Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract...

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK,...